Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck
This is an open-label, exploratory, biomarker study of intravenous temsirolimus given once weekly for 3 weeks to newly diagnosed, advanced stage head and neck cancer subjects prior to beginning their standard therapy for their specific disease. The primary objective of this study is to identify biomarkers of temsirolimus activity.
|Study Design:||Time Perspective: Prospective|
|Official Title:||An Exploratory Biomarker Trail of Temsirolimus in Subjects With Newly Diagnosed Advanced Stage Squamous Cell Carcinoma of the Head & Neck|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00195299
|United States, Louisiana|
|Shreveport, Louisiana, United States, 71130|
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|